XML 81 R60.htm IDEA: XBRL DOCUMENT v3.7.0.1
License Agreements - Additional Information (Detail)
Dec. 24, 2015
USD ($)
Installment
Dec. 16, 2015
USD ($)
Nov. 19, 2015
USD ($)
Installment
Dec. 31, 2016
USD ($)
Sentynl Therapeutics, Inc.        
License And Collaboration Agreements [Line Items]        
Consideration receivable under agreement     $ 12,000,000  
Upfront payment receivable under agreement     8,000,000  
Contingent consideration receivable under agreement     $ 4,000,000  
Number of one-time future milestone payments | Installment     2  
Sentynl Therapeutics, Inc. | Minimum        
License And Collaboration Agreements [Line Items]        
Contingent consideration threshold, net sales     $ 25,000,000  
Sentynl Therapeutics, Inc. | Maximum        
License And Collaboration Agreements [Line Items]        
Contingent consideration threshold, net sales     $ 35,000,000  
Midatech Pharma PLC        
License And Collaboration Agreements [Line Items]        
Consideration receivable under agreement $ 29,750,000      
Upfront payment receivable under agreement 3,750,000      
Contingent consideration receivable under agreement $ 26,000,000      
Number of one-time future milestone payments | Installment 4      
Midatech Pharma PLC | Minimum        
License And Collaboration Agreements [Line Items]        
Contingent consideration threshold, net sales $ 12,000,000      
Midatech Pharma PLC | Maximum        
License And Collaboration Agreements [Line Items]        
Contingent consideration threshold, net sales $ 70,000,000      
Monosol Rx, LLC        
License And Collaboration Agreements [Line Items]        
Payment of upfront fee   $ 900,000    
Payment of upfront fee, percentage of future milestone payments received   20.00%    
M D Anderson Cancer Center        
License And Collaboration Agreements [Line Items]        
Annual maintenance fee       $ 200,000
Milestone payment       $ 200,000